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Abstract
Background: Retroviruses can acquire not only their own glycoproteins as they bud from the cellular membrane,
but also some cellular and foreign viral glycoproteins. Many of these non-native glycoproteins are actively recruited
to budding virions, particularly other viral glycoproteins. This observation suggests that there may be a conserved
mechanism underlying the recruitment of glycoproteins into viruses. If a conserved mechanism is used, diverse
glycoproteins should localize to a single budding retroviral particle. On the other hand, if viral glycoproteins have
divergent mechanisms for recruitment, the different glycoproteins could segregate into different particles.
Results: To determine if co-packaging occurs among different glycoproteins, we designed an assay that combines
virion antibody capture and a determination of infectivity based on a luciferase reporter. Virions were bound to a
plate with an antibody against one glycoprotein, and then the infectivity was measured with cells that allow entry
only with a second glycoprotein. We tested pairings of glycoproteins from HIV, murine leukemia virus (MLV), Rous
sarcoma virus (RSV), vesicular stomatitis virus (VSV), and Ebola virus. The results showed that glycoproteins that were
actively recruited into virions were co-packaged efficiently with each other. We also tested cellular proteins and
found CD4 also had a similar correlation between active recruitment and efficient co-packaging, but other cellular
proteins did not.
Conclusion: Glycoproteins that are actively incorporated into HIV-1 virions are efficiently co-packaged into the same
virus particles, suggesting that the same general mechanism for recruitment may act in many viruses.
Keywords: Env, Assembly, Pseudotype, Glycoprotein recruitment, CD4, VSV-G, Ebola GP
Background
HIV-1, like other enveloped viruses, can incorporate
glycoproteins from different viruses during assembly,
allowing for an alternative tropism of the formed virion,
a phenomenon known as pseudotyping [1-3]. Despite
pseudotyping being a useful tool for gene delivery in
both research and therapy, the mechanism of pseudotyp-
ing is poorly understood. In some instances, incorpor-
ation may be coincidental, as any glycoprotein present in
the membrane that a virion collects during assembly
might be incorporated in a passive manner. However,
with some retrovirus and glycoprotein pseudotype com-
binations, incorporation appears to be an active process
[4]. This observation raises questions about whether
many enveloped viruses share a basic conserved mech-
anism for acquiring viral glycoproteins during assembly
and what such a mechanism might be.
Incorporation of HIV Env into HIV virions is generally
thought to occur due to physical interactions between
the cytoplasmic tail domain (CTD) of the glycoprotein
and the matrix (MA) domain of Gag (reviewed in [5,6]).
However, for pseudotyped viruses, such an interaction is
unlikely except when the viral proteins are from very
closely related viruses that can exchange structural com-
ponents, such as HIV-1 and HIV-2 [7]. Even for native
Env recruitment, physical interactions mediated by the
CTD of Env are not always necessary. For example, dele-
tion of MLV Env’s CTD does not prevent its enrichment
at viral assembly sites [8]. While the CTD of HIV Env is
required for Env incorporation into HIV particles in
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some cell types, it is not required in others, such as hu-
man embryonic kidney (HEK) 293 cells [9,10]. Deletion
of HIV-1 Env’s CTD allows it to efficiently pseudotype
with virions other than HIV-1 and to be functional with
some HIV-1 Gag MA mutations that are incompatible
with full length Env [11-14]. Similarly, the HIV-1 MA
domain appears to be important only for native Env
incorporation. Deleting most of the MA domain or
replacing the MA domain with heterologous membrane
binding domains still allows efficient pseudotyping of
HIV-1 by MLV Env and VSV-G [15-18]. Thus it is
unlikely that a direct physical interaction between viral
glycoproteins and Gag is the primary mechanism of
active pseudotyping.
Physical interactions mediated by another protein
comprise another possible mechanism of glycoprotein
recruitment. Such an intermediate, tail-interacting pro-
tein (TIP) 47, has been proposed for native HIV-1 Env
recruitment, though its involvement has been called into
question and may act only in specific cell types [19-21].
However, for pseudotyping combinations such as HIV
virions and MLV Env, where the domains most likely to
be involved in such indirect interaction are dispensable,
a simple protein intermediate is also unlikely.
Another candidate for an intermediary of glycoprotein
recruitment is the lipid membrane microdomain of a vir-
ion. Many viruses have been shown to acquire lipids that
are characteristic of lipid rafts [22-24]. Recent studies on
the membranes of HIV-1 virions have shown them to have
a unique composition that shares features of lipid rafts
and tetraspanin enriched microdomains [25-28]. Thus,
an attractive model for glycoprotein recruitment is that
the unique membrane microdomain(s) of an assembling
virion has specific features that attract and/or retain viral
glycoproteins. Consistent with this model, Leung et al.
reported that HIV-1 Env and Ebola glycoprotein (GP) are
present in separate microdomains and are incorporated
into separate individual HIV-1 virions [29].
If some viruses share a common mechanism for glyco-
protein incorporation, one would expect those viruses to
have their glycoproteins efficiently incorporated into the
same individual pseudotyped virion. When mechanisms
differ, for example if different microdomains are used or
if specific direct protein interactions are used, the glyco-
proteins may not be compatible with the same individual
virion, though this will not always be the case. To deter-
mine which glycoproteins might share the same mech-
anism, or at least have compatible mechanisms, for
incorporation, we sought to identify glycoprotein pairs
that could be efficiently incorporated into the same indi-
vidual HIV-1 virion. We found a correlation between the
ability of a glycoprotein to efficiently pseudotype HIV-1
particles and its ability to co-assemble with a different
glycoprotein into the same virion.
Results & discussion
Visualization of glycoprotein recruitment by SEM
We have previously shown that the distribution of glyco-
proteins relative to viral assembly sites can be imaged by
scanning electron microscopy (SEM) [4]. MLV Env and
VSV-G are two glycoproteins that efficiently form infec-
tious pseudotyped particles with HIV-1 and that also
appear highly enriched at HIV-1 assembly sites by SEM.
In contrast, RSV Env forms infectious pseudotyped
particles less efficiently with HIV-1 and is not seen to be
enriched at HIV-1 assembly sites by SEM despite effi-
cient surface expression. By high resolution fluorescence
microscopy, HIV-1 Env has been reported to be concen-
trated on HIV-1 particles [30,31]. We wished to deter-
mine if HIV-1 Env can also be visualized by SEM, if it is
enriched at viral assembly sites, and if MLV Env is
enriched at the same sites. Successful labeling of both
glycoproteins on the same virion using different sized
gold particles would be an indication that the mecha-
nisms of recruitment of the two glycoproteins are com-
patible and may be the same.
Cells plated on a glass coverslip were co-transfected
with plasmids encoding HIV-1 Env and/or MLV Env,
together with a plasmid containing an HIV-1 provirus
lacking Env and encoding mutated late and protease
domains. A day later the cells were prepared as outlined
in the Methods and then visualized by SEM (Figure 1).
Immunogold labeled HIV-1 Env was seen enriched on
budding virions compared with other regions of the
plasma membrane (Figure 1A). When both glycoproteins
were produced, both were enriched on virus particles
with no discernable segregation (Figure 1B). Cross-
reaction of the labeling antibodies was not observed
(data not shown). This result indicates that the recruit-
ment mechanisms for both HIV and MLV glycoproteins
into HIV-1 particles are compatible with each other in
this cell type.
Viral capture and infectivity assay for co-assembly of
glycoproteins
Though SEM can show co-incorporation of different
glycoproteins into the same virus particle, it is a technic-
ally challenging assay that is inherently qualitative. In
order to have a more efficient and quantitative assay for
co-packaging of glycoproteins, we developed a variation
on the traditional antibody-mediated virus capture assay
(Figure 2) [32,33]. To perform this assay, viruses from a
provirus with an intron-interrupted, reverse Gaussia
luciferase gene were produced from cells expressing an
individual viral glycoprotein or a pair of viral glycopro-
teins. The intron-interrupted luciferase gene insured that
only cells infected with the virus, and not any trans-
fected cells, would produce active luciferase [31]. The
concentration of plasmids for each glycoprotein was
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selected to ensure that the glycoprotein was the rate-
limiting component for infectious particle production
and that the glycoproteins all produced roughly equiva-
lent numbers of infectious particles (data not shown).
Antibodies to either of the two glycoproteins were bound
to wells of an enzyme-linked immunosorbent assay
(ELISA) plate followed by addition of the virus. After
allowing virus to be captured by the antibodies, free virus
was washed away with PBS. Cells permissive to virus with
one of the two glycoproteins were then seeded into the
Figure 1 SEM of HIV Env and MLV Env recruitment to viral particles. A) Cells producing HIV-1 Gag and GagPol without functional late or PR
domains, and producing HIV-1 Env were labeled with 10 nm immunogold against HIV-1 Env and then imaged by SEM. B) Cells as in A, but also
producing MLV Env were labeled with 10 nm (small arrow) and 18 nm (large arrow) immunogold against HIV-1 and MLV Envs, respectively, and
then imaged by SEM.
Figure 2 Schematic of co-capture assay. The minimal HIV-1 provirus with an intron interrupted reverse Gaussia luciferase gene as a reporter
and the desired glycoproteins were transfected into 293FT cells to produce virus. The virus was then captured by antibodies against the
glycoproteins or no antibody in the wells of an ELISA plate. Unbound virus was washed away from all wells except a straight infectivity positive
control. Cells susceptible to infection mediated by one or the other of the glycoproteins were then added to the wells and two days later
luciferase production was assayed.
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wells. After two days, infection efficiency was quantified
by detection of luciferase activity. The infection efficiency
of virus captured with antibody against the infection
incompetent glycoprotein was used to measure the co-
packaging efficiency. For controls, viruses were added to
wells with no antibody and either washed away (no anti-
body capture) or not washed away (straight infection)
prior to cell seeding. This assay will be referred to as a
co-capture assay from here on.
We first tested MLV Env and HIV Env with the
co-capture assay to see if the result from SEM could be
recapitulated (Figure 3A & B). Using virus produced
only with MLV Env, infection of 293 T cells expressing
the MLV Env receptor, mouse cationic amino acid trans-
porter protein 1 (mCAT-1), after virus capture with an
antibody against MLV Env yielded a luciferase signal
2.5-fold higher than with straight infection, indicating
efficient capture (Figure 3A). The greater efficiency from
the capture compared with straight infection was fre-
quently observed, and we suspect that it is due to immo-
bilized virus having a greater chance of contact with
cells compared with free virus. Virus captured with anti-
body against HIV Env or without any antibody yielded
signal 0.08- and 0.03-times that of straight infection,
respectively. Virus produced with HIV Env alone cannot
infect 293 T mCAT-1 cells as they lack CD4, the receptor
for HIV Env, and thus this virus resulted in no luciferase
signal under any of the conditions. Virus produced with
both MLV Env and HIV Env was efficiently captured with
antibody against either glycoprotein. Capture of this virus
with an antibody against MLV Env or HIV Env yielded
luciferase signal 2.3- or 3.6-fold higher than straight infec-
tion, respectively. Capture with no antibody yielded a
signal that was 0.05-times that of straight infection.
In the reciprocal cell line which expresses CD4, TZM-
bl, virus produced with HIV Env alone yielded a lucifer-
ase signal when captured with antibody against HIV
Env, but not when captured with antibody against MLV
Env or no antibody (13.8-fold, 0.17-times & 0.13-times
that of straight infection, respectively) (Figure 3B). Virus
produced with MLV Env alone cannot infect TZM-bl
cells as these cells lack mCAT-1, the receptor for MLV
Env, and thus this virus yielded in no luciferase signal
under any of the conditions. Virus produced with both
glycoproteins could be captured with antibody against
either HIV Env or MLV Env (6.5- and 1.9-fold of
straight). Capture with no antibody yielded a signal that
was 0.07-times that of straight infection. These results
Figure 3 Co-capture of HIV-1 Env and MLV Env. A & B) Co-capture was performed using virus with HIV-1 Env and MLV Env. Luciferase signal
from A) 293 T mCAT-1 cells or B) TZM-bl cells infected with virus produced in the presence of MLV Env, HIV-1 Env or both Envs and then
subjected to the following: anti-MLV Env capture + wash, anti-HIV capture + wash, no antibody capture + wash & straight infection (no antibody,
no wash). The signal was normalized to the straight infection positive control from the relevant single glycoprotein virus sample. All graphs are
the average of at least three independent experiments unless indicated otherwise and show standard deviation. C & D) Luciferase signal as
before from C) 293 T mCAT-1 and D) TZM-bl cells infected with virus produced with only MLV Env, only HIV Env or a mixture of the two viral
supernatants. A & B were the average of at least 3 independent experiments, C & D were the average of two experiments.
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indicate that HIV Env and MLV Env are present in the
same individual virions, consistent with what we observed
by SEM.
To rule out the possibility that co-capture infection
was occurring due to viral particles with different glyco-
proteins stuck to each other, and not from glycoproteins
in the same individual virion, we mixed supernatants
that contained viruses produced with only one or the
other glycoprotein and performed the co-capture assay
(Figure 3C & D). With the mixed viruses, we did not
observe co-capture. Virus captured with antibody against
HIV Env did not produce a signal with 293 T mCAT-1
cells, and virus captured with antibody against MLV Env
did not produce a signal with TZM-bl cells. Thus it is
unlikely that virus was captured indirectly by one virus
sticking to another, and thus the signal we observed
from virus produced with both Envs was in fact due to
both glycoproteins being present in the same virion.
We performed this co-capture assay for all pairings of
HIV Env, MLV Env, RSV Env, VSV-G and Ebola GP
(Figure 4A-F). As before, virus produced with only one
glycoprotein was not captured with antibodies against
other glycoproteins, and could only infect specific target
cell lines (data not shown). The exceptions to the latter
are VSV-G and Ebola GP, which mediate infection of a
wide range of cell lines, including all the ones we used
here. So that these glycoproteins would not mediate in-
fection when targeted for capture, we used entry defect-
ive mutants of VSV-G (A117R) and Ebola GP (G87A
and F88A) in parallel to the wildtypes [34,35]. All glyco-
proteins were efficiently co-packaged except for RSV
Env. With all pairings of HIV Env, MLV Env, VSV-G
and Ebola GP there was significant enrichment of infect-
ivity with the reciprocal antibody compared to the no
antibody control (Figure 4A-E).
The antibody used to capture RSV Env-containing vi-
ruses appeared to be less efficient at self-capture, which
casts doubt on its apparent inefficiency at co-capture
(Figure 4C). RSV Env is not actively recruited to HIV-1
virions despite efficient surface expression and thus inef-
ficiently incorporated during assembly, likely making
virions very sensitive to neutralization by the capture
antibody [4]. However, RSV Env co-capture was also in-
efficient when virus was captured with antibodies against
the reciprocal glycoproteins (Figure 4A, B, D-F). Since
the other antibodies were efficient at self-capture, these
data indicate that RSV Env is not co-packaged efficiently
with the other viral glycoproteins (Figure 4C).
While all the glycoproteins other than RSV Env were
efficiently co-packaged with each other, capture of MLV
Env and VSV-G-containing viruses with antibody against
MLV Env, followed by infection with VSV-G was 0.35-
fold that of straight infection (Figure 4D & F), while the
reciprocal was 1.77-fold that of straight (Figure 4B & F).
Though capture of VSV-G containing virus with anti-
body against MLV Env was generally inefficiently, it was
still 5-fold greater than capture with an antibody against
RSV Env. Since MLV Env and VSV-G-containing viruses
were efficiently captured with antibody against VSV-G,
the data overall suggest MLV Env and VSV-G do effi-
ciently co-package, if slightly less efficiently than other
pairings (Figure 4B & F). In total, the data from the co-
capture assay suggest that co-packaging is most efficient
among glycoproteins that are actively recruited to viral
assembly sites.
We did not expect Ebola GP to be co-packaged with
HIV Env, as these two glycoproteins have been reported
to segregate into distinct particles [29]. However, we
found that Ebola GP is co-packaged with all of the
glycoproteins tested except for RSV Env, as noted above
(Figure 4A-F). The reason for this discrepancy with the
previous study is not readily apparent and may simply
reflect differences in reagents or assay methods. Ebola
GP is known to form pseudotyped virions effectively
with HIV-1 suggesting that it is actively recruited into the
assembling particles [36]. That Ebola GP is efficiently co-
packaged with the glycoproteins that are actively recruited
during assembly also suggests that it is actively recruited.
Cellular membrane proteins co-packaging efficiency
We wished to determine if cellular proteins were co-
packaged in a similar manner as observed with the viral
glycoproteins. To test co-packaging of cellular proteins,
we constructed expression vectors to produce the GFP-
tagged cellular membrane proteins CD4, basal cell adhe-
sion molecule (BCAM), CD93, Glypican-3 (GPC3) and
Natriuretic Peptide Receptor C (NPR), as well as a GPI-
anchored GFP. This collection of proteins was chosen to
include single pass type I transmembrane proteins with
short cytoplasmic tails and GPI-anchored proteins. CD4,
BCAM, CD93, GPC3 and NPR have predicted cytoplas-
mic tails 38, 56, 45, 8 and 37 amino acids in length, re-
spectively. GPI anchored proteins are incorporated into
HIV-1 particles, but reports have varied on the efficiency
of incorporation [25,26,37-42]. CD4 is known to be effi-
ciently incorporated into HIV-1 virions, but it has not
been shown to be actively recruited [43,44]. The produc-
tion and surface localization of each of these proteins,
along with the YFP-tagged MLV Env, was verified by fluor-
escence detection of total GFP/YFP and Alexa Fluor 647
labeled surface GFP/YFP by flow cytometry (Figure 5A).
Concentrations for each cellular glycoprotein expression
plasmid were adjusted to result in similar surface labeling
as 5 ng of the MLV Env plasmid used previously. The
co-capture assay was then performed with each of these
cellular proteins and VSV-G (Figure 5B). Capture effi-
ciency was greater when more plasmid was used in
the transfection for each protein, but differences in
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efficiency were observed among the different proteins.
Of the cellular proteins, CD4 appeared to be co-
packaged with VSV-G the most efficiently, followed
BCAM, CD93, GPI, NPR and GPC3. Although the mean
viral capture was higher than the no antibody control
with all of the cellular proteins, in many cases the
enhancement was not statistically significant.
Given that we observed efficient co-packaging only
amongst actively recruited viral glycoproteins, and that
CD4 was efficiently co-packaged with VSV-G, we expected
CD4 and perhaps BCAM to be actively recruited to viral
assembly sites and the other cellular proteins to be ineffi-
ciently recruited or perhaps even excluded. To see if these
predictions were true, we performed SEM as before with
the GPF-tagged CD4, GPI anchor, BCAM and CD93 using
an anti-GFP primary antibody (Figure 6A-D). CD4 was
indeed seen enriched on budding virions while the dis-
tributions of the other glycoproteins were more random.
Thus the pattern observed with the viral glycoproteins
was reinforced with the cellular proteins. Because CD4
Figure 4 Diverse viral glycoproteins can be co-packaged. Co-capture was performed using all paired combinations of HIV-1 Env, MLV Env,
RSV Env, VSV-G and Ebola GP. Graphs show the luciferase signal from infection mediated by A) HIV-1 Env in TZM-bl cells, B) MLV Env in 293 T
mCAT-1 cells, C) RSV Env in 293 T TVA cells, D) VSV-G in 293 T-derived cells or E) Ebola GP in 293 T-derived cells when virus was produced with
the above glycoproteins and then captured with the indicated antibody. Red text with a # indicate the use of an entry defective VSV-G or Ebola
GP as the target for capture. Signal was normalized to the straight infection for each experiment prior to averaging. The average fold increase
from antibody capture/no antibody capture is shown for each co-capture sample. F) The average percent capture for each paring relative to the
straight infection is shown. All graphs are the average of at least three independent experiments and standard deviations are shown. *p < 0.05;
**p < 0.01; NS p > 0.05.
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plays a critical role in the HIV-1 life cycle, we decided to
see if untagged wildtype CD4 was similarly recruited
(Figure 7). For this imaging we used a late domain mu-
tant Gag and a biotin-conjugated anti-CD4 primary
antibody. Under these conditions the CD4 was labeled
very efficiently and was strikingly localized to viral parti-
cles, indicating that CD4 is efficiently and actively incor-
porated into virus during HIV-1 budding.
Conclusions
Our data demonstrate that various glycoproteins can be
efficiently co-packaged into the same individual virion
only when the glycoproteins are actively recruited to
assembly and budding sites, while glycoproteins that are
not actively recruited are not efficiently co-packaged.
The compatibility of recruitment of different glycopro-
teins is consistent with a mechanism of recruitment that
is the same for diverse viruses, but does not rule out dis-
similar compatible mechanisms. Whereas co-packaging
incompatibility indicates different mechanisms of glyco-
protein recruitment. Interestingly, cellular proteins can
also be actively recruited, though of the cellular proteins
that we assayed, only CD4 was actively recruited. Fur-
ther testing would be needed to determine if active
Figure 5 Co-capture using cellular glycoproteins. Co-capture was performed on virus produced from cells transfected as before using VSV-G
and the indicated amounts of GFP-tagged cellular proteins or YFP-tagged MLV Env. A) The surface expression of the indicated proteins in
transfected cells was assayed by surface labeling GFP with an anti-GFP antibody conjugated to Alexa Fluor 647, which was detected by flow
cytometry. B) The luciferase signal from the anti-GFP captured samples and the no-antibody captured samples normalized to the straight control
is shown. The average fold increase of antibody/no antibody is shown for each pair. All graphs are the average of at least three independent
experiments and standard deviations are shown. *p < 0.05; **p < 0.01; NS p > 0.05.
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recruitment of cellular proteins is as rare as our data
suggest. Regardless, the identification of classes of pro-
teins that are and are not actively recruited may aid in
identifying common features that facilitate active recruit-
ment and aid in elucidating the mechanisms by which
they function.
Methods
Cells, plasmids and antibodies
HEK-293 FT (Invitrogen), 293 T mCAT-1 (Walter
Mothes, Yale University), 293 T TVA (John Young,
Scripps Research Institute) and HeLa TZM-bl (NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH:
Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme
Inc.) were maintained in DMEM supplemented with
10% fetal bovine serum, 2 mM glutamine and 10 mM
vitamins. For HIV infectivity we used a pNL4-3 deriva-
tive without Env, Vpu, Vpr, Vif and Nef, and with a
reverse intron interrupted Gaussia luciferase reporter,
HIV-Gluc [32]. For SEM we used a similar pNL4-3
derivative that has Puro-Cherry as the reporter and with
mutations in both the late domain and PR active site or
a CMV driven late domain mutant Gag previously
described [4]. For viral glycoproteins we used plasmids
expressing codon optimized consensus B-clade HIV Env
(Beatrice Hahn, University of Pennsylvania [45]), MLV
Env with a YFP tag in the SU subunit (Walter Mothes,
Yale University [46]), RSV Env (Eric Hunter, Emory University
[47]), VSV-G (NIH AIDS Reagent Program, Division of
AIDS, NIAID, NIH: Dr. Lung-Ji Chang [48]) and flag
Figure 6 Recruitment of cellular proteins to viral particles. SEM was performed as before with 10 nm immunogold labeling of the GFP tag of
A) CD4, B) GPI, C) BCAM or D) CD93. Some of the immunogold particles are out of the plain of focus, thus leading to different apparent size
and intensity.
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tagged Ebola GP with the mucin domain deleted (tag added
to plasmid from David Sanders, Perdue University [49]).
Entry defective versions of VSV-G and Ebola GP were made
by introducing A117R mutation or G87A and F88A muta-
tions into VSV-G or Ebola GP, respectively, by standard
cloning techniques [34,35]. For the cellular glycoproteins we
cloned the cDNA coding sequence for post-leader peptide
sequence of CD4 (Nathaniel Landau, New York University),
BCAM (GenBank: BC050450.1), CD93 (GenBank: BC0280
75.1), GPC3 (GenBank: BC035972.1), NPR (GenBank: BC
131540.1) or the GPI anchor peptide from CD55 (GenBank:
NM_000574.3) downstream of GFP with an influenza
HA leader peptide using standard cloning procedures. A
CMV driven wildtype CD4 IRES GFP plasmid was used
for the SEM in Figure 7. For capture of virions we used
2G12 against HIV Env (NIH AIDS Reagent Program,
Division of AIDS, NIAID, NIH: Dr. Hermann Katinger),
polyclonal rabbit anti-GFP for MLV Env and cellular
glycoproteins, 8C5.4 against RSV Env (Eric Hunter,
Emory University [50]), 8G5F11 against VSV-G (hybrid-
oma, KeraFAST) and M2 anti-flag (F1804 Sigma) for
Ebola GP. Surface labeling of GFP was done using Alexa
Fluor 647 conjugated rabbit anti-GFP (Invitrogen). For
SEM monoclonal anti-GFP 20 mouse antibody (G6539
Sigma), 2G12 anti-HIV-1 Env antibody and anti-CD4
biotin conjugate antibody (MHCD0415 Caltag) were
used for primary labeling. For secondary labeling,
10 nm or 18 nm gold conjugated anti-mouse, 10 nm
anti-human and 12 nm anti-biotin antibodies were used
(EM.GMHL10 BBI, 115-215-146 Jackson Laboratories,
EM.GAHL10 BBI, EM.GAB12 BBI).
Co-capture assay
To produce virus to use in the capture assay HEK-293
FT cells were transfected with HIV-Gluc (500 ng) and
the viral glycoprotein plasmids so that the viral glyco-
proteins would be in a limiting amount (10 ng, 5 ng,
20 ng, 10 ng and 10 ng for HIV, MLV, RSV, VSV and
Ebola, respectively) using polyethylenimine. These amounts
were arrived at empirically from titration curves of each
glycoprotein in order for the infectivity to be similar for
all of them, though variability existed between subse-
quent experiments (data not shown). For the cellular
glycoproteins the amounts used are indicated in Figure 5
and represent amounts that had similar levels of surface
labeling as 5 ng of the MLV Env plasmid. Two days after
transfection the supernatants were collected and proc-
essed with one freeze-thaw cycle. Antibodies were
bound to the wells of an ELISA plate by adding 20 μL of
PBS with or without antibody to the wells and incubated
overnight at 4°C. The overlay was then aspirated and
100 μL of blocking buffer (PBS with 1% BSA, 5% su-
crose & .05% sodium azide) was incubated in the wells
for one hour. The blocking buffer was then removed
and 10 μL of supernatant with equal volume of PBS was
added to the wells. Following a three hour incubation
with virus at 37°C, the supernatant was removed and all
wells except those meant for positive infectivity controls
were washed twice with 100 μL of PBS. 20 μL of PBS
was then added to the washed wells to normalize the
volume to the positive controls and then the relevant
cells were plated into the wells for infection. Two days
after infection, 20 μL of supernatant from each well was
transferred to a black 96 well plate and assayed for lucif-
erase activity by adding 25 μL of coelenterazine (Nano-
Light Technology) and reading the luminescence with a
Turner Biosystems’ Veritas luminometer. Statistical p
values were calculated by performing a one-sample
t-test on the natural logarithm of (antibody capture
signal/no antibody capture signal) from each experiment.
Cellular GFP detection
Cells were transfected as for the capture assay and two
days later, after the removal of the supernatant, the cells
were washed with PBS and then incubated with 10 mM
EDTA in PBS. Once the cells had disassociated they
were transferred to tubes with 5% rabbit serum for
blocking. Samples were kept at 4°C for all subsequent
Figure 7 Wildtype CD4 recruitment to viral particles. SEM was
performed as before using wildtype CD4 and a late domain mutant
of HIV-1 Gag. An anti-CD4 antibody conjugated to biotin and a
12 nm gold anti-biotin antibody were used to label CD4.
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steps until fixation. Following 30 minutes of blocking,
the cells were pelleted by centrifugation and then incu-
bated with the Alexa Fluor 647 anti-GFP antibody for
one hour in 10 mM EDTA PBS. Cells were then gently
pelleted again and washed with PBS by resuspending
and pelleting, and then fixed in 4% paraformaldehyde in
PBS for at least 20 minutes. The fixed cells were then
pelleted and resuspended in PBS before being analyzed
on an Accuri C6 flow cytometer to detect total GFP
fluorescence and surface GFP labeled with the Alexa
Fluor antibody.
Scanning electron microscopy
Imaging of cells by SEM was done as previously de-
scribed [4]. Briefly, 293 T mCAT-1 or 293 T TVA cells
were plated onto glass coverslips with a thin-layer gold
coat in a grid pattern and transfected with the late do-
main mutant and glycoprotein plasmids using polyethy-
lenimine. Fluorescence microscopy was used to map
transfected cells prior to fixation and antibody labeling
of the glycoproteins. After critical point drying and car-
bon evaporation coating, samples were imaged with a
Hitachi S4700 FE SEM at the University of Missouri
Electron Microscopy Core Facility. Image brightness and
contrast were adjusted in Microsoft PowerPoint for clear
resolution of topology and gold particles.
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